Envestnet Asset Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Envestnet Asset Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,696	Closed	-$16.2K	–	4207
2023 Q3	$16.2K	Hold	2,696	–	–	﹤0.01%	3983
2023 Q2	$18.6K	Hold	2,696	–	–	﹤0.01%	3925
2023 Q1	$42.3K	Hold	2,696	–	–	﹤0.01%	3864
2022 Q4	$53.9K	Hold	2,696	–	–	﹤0.01%	3864
2022 Q3	$48K	Sell	2,696 -55	-2%	-$1.18K	﹤0.01%	3811
2022 Q2	$61K	Buy	2,751 +247	+10%	+$5.51K	﹤0.01%	3802
2022 Q1	$70K	Hold	2,504	–	–	﹤0.01%	3835
2021 Q4	$114K	Hold	2,504	–	–	﹤0.01%	3748
2021 Q3	$209K	Sell	2,504 -2,500	-50%	-$207K	﹤0.01%	3488
2021 Q2	$475K	Hold	5,004	–	–	﹤0.01%	3024
2021 Q1	$833K	Buy	+5,004	New	+$662K	﹤0.01%	2529

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PPW

Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

Envestnet Asset Management's ONCT Position: Q4 2023 in Review

Envestnet Asset Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2023, closing a stake of 2,696 shares — an estimated $16.2K sold.

Envestnet Asset Management first reported a position in ONCT in Q1 2021 and held it in 11 quarters. The position peaked at $833K in Q1 2021. 38 funds tracked by Wall St. Rank hold ONCT as of Q4 2023.

Envestnet Asset Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Envestnet Asset Management sold 2,696 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $16.2K.
Envestnet Asset Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
Envestnet Asset Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $833K in Q1 2021.
38 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Envestnet Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.